Home › Funds › Marshall Wace › TRVI
Marshall Wace position in TRVI
TREVI THERAPEUTICS INC · Health Care
Latest position (Q2 2026)2.67M sh
Reported value held$49.87M
Portfolio Weight0.04%
First reportedQ1 2022
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2022 | 23.40K | $52.00K | New |
| Q3 2022 | 128.32K | $198.00K | New |
| Q3 2024 | 81.12K | $270.95K | New |
| Q4 2024 | 42.92K | $176.84K | Reduce |
| Q1 2025 | 2.55M | $16.07M | Add |
| Q2 2025 | 2.48M | $13.55M | Reduce |
| Q3 2025 | 4.84M | $44.30M | Add |
| Q4 2025 | 4.58M | $57.35M | Reduce |
| Q1 2026 | 3.97M | $47.31M | Reduce |
| Q2 2026 | 2.67M | $49.87M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding TRVI
- Fidelity Management & Research (FMR) 12.56M sh · $234.30M · Q2 2026
- BlackRock Inc 11.16M sh · $208.04M · Q2 2026
- Wellington Management Group 5.68M sh · $106.02M · Q2 2026
- Vanguard Group 6.43M sh · $80.56M · Q4 2025
- Geode Capital Management 2.93M sh · $54.62M · Q2 2026
- Viking Global Investors 1.54M sh · $28.81M · Q2 2026
- Bank of America Corp 1.53M sh · $28.59M · Q2 2026
- Goldman Sachs Group 1.20M sh · $22.43M · Q2 2026
- Northern Trust Corp 1.01M sh · $18.76M · Q2 2026
- Charles Schwab Investment Management 965.40K sh · $18.00M · Q2 2026
- Balyasny Asset Management 845.09K sh · $15.76M · Q2 2026